The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://haleemarnuz645371.blue-blogs.com/46921052/glp-3-retatrutide-a-comparative-analysis